

1 Proteomic analysis and protein expression during sporozoite excystation of  
2 *Cryptosporidium parvum* (coccidia, Apicomplexa)

3

4 William J. Snelling<sup>1</sup>, Qishan Lin<sup>2</sup>, John E. Moore<sup>3</sup>, B. Cherie Millar<sup>3</sup>, Fabio Tosini<sup>4</sup>,  
5 Edoardo Pozio<sup>4</sup>, James S.G. Dooley<sup>1</sup>, and Colm J. Lowery<sup>1\*</sup>

6

7 <sup>1</sup>Centre for Molecular Biosciences, School of Biomedical Sciences,

8 University of Ulster, Cromore Road, Coleraine, County Londonderry, N. Ireland,  
9 BT52 1SA.

10 <sup>2</sup>UAlbany Proteomics Facility, Centre for Functional Genomics, University of  
11 Albany, One Discovery Drive, Rensselaer, NY 12144.

12 <sup>3</sup>Northern Ireland Public Health Laboratory, Department of Bacteriology,  
13 Belfast City Hospital, Belfast, N. Ireland, BT9 7AD.

14 <sup>4</sup>Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto  
15 Superiore di Sanità, Rome, Italy.

16

17 \*: To whom correspondence may be addressed: Tel: +44 (0)28 70323528; Fax: +44  
18 (0)28 7032 4375; Email [cj.lowery@ulster.ac.uk](mailto:cj.lowery@ulster.ac.uk).

19

20 Running title: Analysis of *Cryptosporidium parvum* proteome

21

22 Key words: *Cryptosporidium parvum*, excystation, proteomics, sporozoites, oocysts,  
23 vaccine development

- 1 **Abbreviations:**
- 2 AC: apical complex
- 3 AdhE: acetaldehyde reductase plus alcohol dehydrogenase
- 4 AP: anterior pole
- 5 ARM: armadillo repeat domain
- 6 CPV: capsid protein
- 7 DAPI-PI: 4',6'-diamidino-2-phenylindole-propidium iodide
- 8 DG: dense granules
- 9 FA: formic acid
- 10 GIPLs: glycosylinositol phospholipids
- 11 GPI: glycosylphosphatidylinositol
- 12 HDAC: histone deacetylase interacting domain
- 13 HSP: heat shock protein
- 14 IAA: iodoacetamide
- 15 IDA: integrated data appliance
- 16 LCCL: Limulus factor C, cochlear protein Coch-5b2 and late gestation lung protein
- 17 MBF1: multiprotein bridging factor type 1
- 18 M: micronemes
- 19 MT: mitochondrion
- 20 N: nucleus
- 21 OW: oocyst wall
- 22 PP: posterior pole
- 23 R: rhoptry
- 24 RB: refractile body
- 25 S: scissure

- 1 SPO: sporozoite
- 2 TBP: tributylphosphine
- 3 TCTP: translationally controlled tumor protein

## 1 SUMMARY

2 Cryptosporidiosis, caused by coccidian parasites of the genus *Cryptosporidium*, is a  
3 major cause of human gastrointestinal infections and poses a significant health risk,  
4 especially to immunocompromised patients. Despite intensive efforts for more than  
5 20 years, there is currently no effective drug treatment against these protozoa. This  
6 study examined the zoonotic species *Cryptosporidium parvum* at two important stages  
7 of its life cycle; the non-excysted (transmissible) and excysted (infective) forms. To  
8 increase our understanding of the molecular basis of sporozoite excystation, LC-  
9 MS/MS coupling with a stable isotope N-terminal labelling strategy using iTRAQ™  
10 reagents was employed on soluble fractions of both non-excysted and excysted  
11 sporozoites, i.e. sporozoites both inside and outside oocysts were examined.  
12 Sporozoites are the infective stage which penetrate small intestinal enterocytes. Also,  
13 to increase our knowledge of the *C. parvum* proteome, shotgun sequencing was  
14 performed on insoluble fractions from both non-excysted and excysted sporozoites.  
15 In total 303 *C. parvum* proteins were identified, 56 of which, hitherto described as  
16 being only hypothetical proteins, are expressed in both excysted and non-excysted  
17 sporozoites. Importantly, we demonstrated that the expression of 26 proteins increase  
18 significantly during excystation. These excystation induced proteins included  
19 ribosomal proteins, metabolic enzymes, and heat shock proteins. Interestingly, three  
20 Apicomplexa-specific proteins and five *Cryptosporidium*-specific proteins augment in  
21 excysted invasive sporozoites. These eight proteins represent promising targets for  
22 developing vaccines or chemotherapies that could block parasite entry into host cells.

## 1 INTRODUCTION

2 The protozoan parasite *Cryptosporidium parvum*, which causes acute  
3 gastroenteritis in both humans and animals, is considered an important pathogen all  
4 over the world (1). *Cryptosporidium* is one of several genera in the phylum  
5 Apicomplexa, whose members share a common apical secretory apparatus mediating  
6 locomotion and tissue or cellular invasion (2). There are currently 16 recognised  
7 species in this genus (3), all of which have 4 naked sporozoites, contained within a  
8 thick walled oocyst (Fig 1A); the resistant and transmissible form of these parasites  
9 (4). Species of the genus *Cryptosporidium* have a complex life cycle. Upon  
10 ingestion, excystation of viable oocysts, 4-6 µm diameter for intestinal species and  
11 gastric species are slightly larger, is triggered (5,6). Following excystation,  
12 sporozoites (Fig 1B; the infective stage) attach to the intestinal epithelium, are  
13 enveloped by the apical membrane and reside in an intracellular, extracytoplasmic  
14 parasitophorous vacuole (5,7). In this peculiar niche, the parasite undergoes an  
15 endogenous asexual and sexual reproductive development (Fig. 1C), culminating in  
16 the production of an encysted stage discharged in the faeces of their host (6,8).  
17 Coccidian oocyst stages are highly resistant to environmental stress and treatments,  
18 e.g. chemical disinfection, which is attributed to a durable oocyst wall; a complex  
19 protective barrier consisting of a double layer of a protein-lipid-carbohydrate matrix,  
20 allowing the parasite to stably persist outside hosts (2,6). *Cryptosporidium parvum*  
21 causes self-limited watery diarrhoea in immunocompetent subjects, but is life-  
22 threatening in immunocompromised patients (1,9,10). Cryptosporidiosis is also  
23 responsible for significant neonatal morbidity in farmed livestock and causes weight  
24 loss and growth retardation, leading to large economic losses (11). *Cryptosporidium*  
25 *parvum* is transmitted by fecal contamination of food or water or by accidental

1 ingestion of infectious oocysts during water-related recreational activities (12). In  
2 1993, the largest *Cryptosporidium* spp. outbreak was registered in Milwaukee,  
3 Wisconsin, USA where 403,000 people were infected through contaminated drinking  
4 water (13), with associated economic costs of \$31.7 million in medical costs and  
5 \$64.6 million in productivity losses (14). Over the last two decades increasing  
6 numbers of cryptosporidiosis outbreaks have been recorded in developed countries  
7 and the importance of the zoonotic species *C. parvum* is being recognized by both  
8 government agencies and the global scientific community (15,16). Unlike many  
9 organisms belonging to the phylum Apicomplexa, such as *Plasmodium* spp. and  
10 *Toxoplasma gondii*, there is no clinically proven effective drug treatment against  
11 *Cryptosporidium* spp. (17). Proteomic profiling is a useful approach for obtaining a  
12 global overview of the proteins present in a system under differing conditions and can  
13 aid in understanding the molecular determinants involved with pathogenesis and  
14 vaccine development (18). Compared with other Apicomplexans, e.g. *Toxoplasma*  
15 *gondii*, both the limited supply of purified parasite material and the lack of  
16 transfection systems have restricted analyses of proteins in parasites of the genus  
17 *Cryptosporidium* (15). The genomic analysis of *C. parvum* and the closely related *C.*  
18 *hominis* (19) have revealed extremely streamlined metabolic pathways and a reliance  
19 on hosts for nutrients (20). *Cryptosporidium parvum* has an animal-type O-linked  
20 glycosylation pathway and >30 predicted surface proteins with mucin-like segments  
21 (21).

22

23 The mechanisms involved in *Cryptosporidium* spp. excystation are incompletely  
24 understood, although roles for both host and parasite-derived components are  
25 recognized, little is known about their precise involvements (5). In vitro excystation

1 protocols for *C. parvum* mimic host-derived signals, including temperature (37°C),  
2 pH fluctuations, and bile salts (5). We adopted an accepted *in vitro* excystation  
3 method (22) and analyzed *C. parvum* proteins at two key stages, both the transmissive  
4 (oocysts) and infective stages (sporozoites), of its life cycle (5,6). Thus, as well as  
5 evaluating the proteome of *C. parvum*, a major aim of our study was to identify  
6 proteins which demonstrated significant increases of expression during oocyst  
7 excystation, a vital step of the pathogenesis of these coccidian (6). This was achieved  
8 by employing LC/MS and iTRAQ<sup>TM</sup> reagent isotope labelling, providing a powerful  
9 tool for the identification and quantification (23,24) of soluble *C. parvum* proteins.  
10 Using LC/MS with iTRAQ the protein expression in non-excysted and excysted  
11 soluble *C. parvum* oocyst fractions was compared. Then using shotgun peptide  
12 sequencing (25) the insoluble protein content of non-excysted and excysted oocysts  
13 was also analyzed.

14

## 1 **EXPERIMENTAL PROCEDURES**

2 **Oocyst isolation and sporulation.** To recover high numbers of *C. parvum* oocysts,  
3 with minimal faecal and bacterial contaminants (26),  $4 \times 10^8$  *C. parvum* oocysts  
4 (strain code ISSC162) were recovered from experimentally infected calves using  
5 faeces purification with sucrose and Percoll density gradients (27). Purified oocysts  
6 were stored at 4°C for no longer than three weeks. Using 4',6'-diamidino-2-  
7 phenylindole-propidium iodide assays (DAPI-PI) assays (28), oocyst viability was  
8 determined to be at least 92%. To obtain free sporozoites, half of the oocysts ( $2 \times$   
9  $10^8$ ) were excysted as previously described (22). Briefly, oocysts were resuspended  
10 in 10 mM HCl (Sigma, St. Louis, MO) and incubated at 37°C for 10 min. The  
11 suspension was centrifuged at 3,000 x g for 5 min. The pellet was then resuspended  
12 in 2 mM sodium taurocholate in PBS (Sigma), incubated at 15°C for 10 min, followed  
13 by 37°C for 8 min and a high level of excystation i.e., at least 90%, was confirmed  
14 (29).

15  
16 ***C. parvum* lysis, protein precipitation and fraction preparation.** All excysted and  
17 non-excysted oocysts were solubilized (30 min at 4°C) in lysis buffer [50 mM Tris  
18 (BioRad, Hercules, CA) 5 mM EDTA (Sigma), 5 mM iodoacetamide (IAA) (Sigma),  
19 0.1 mM N- $\alpha$ -p-tosyl-L-lysyl chloromethyl ketone (Sigma), 1 mM  
20 phenylmethylsulfonyl fluoride (Sigma), 1% (wt/vol) octyl-glucoside (Roche,  
21 Hertfordshire, UK)], and stored at -80°C (30). Upon thawing, samples were sonicated  
22 with twenty 10 s pulses (50 W) on ice, with 1 min intervals and were then  
23 ultracentrifuged at 4°C (20,000 x g, 30 min) to separate the soluble and insoluble  
24 fractions (30). Insoluble fractions were then rinsed 3 times with ice-cold PBS and  
25 stored at -80°C. Proteins in soluble lysate fractions were then precipitated by mixing

1 oocyst lysates with eight volumes of ice-cold acetone, 1 volume of TCA and 0.7%  
2 (wt/vol) 2-Mercaptoethanol at -20°C for 1 h, and then centrifuged at 18,000 x g for 15  
3 min at 4°C (31,32). Pellets of precipitated soluble proteins were then washed with 1  
4 ml of ice-cold acetone, centrifuged at 18,000 x g for 15 min at 4°C, covered in a layer  
5 of ice-cold acetone, and stored at -80°C.

6

### 7 **Trypsin digestion, shotgun peptide sequencing and iTRAQ isobaric labelling.**

8 The pellets (soluble and insoluble fractions) were re-suspended in 400 µl sample  
9 preparation buffer [100 mM Tris-HCl, 8 M urea, 0.4% SDS, 5 mM tributylphosphine  
10 (TBP), pH 8.3] and placed on ice (33). Sample mixtures were sonicated with five 20 s  
11 pulses (50 W), with 1 min intervals on ice, followed by IAA alkylation at room  
12 temperature for 1 h (34). Samples were then ultracentrifuged at 100,000 x g for 20  
13 min at room temperature. Protein concentrations were measured using a MicroBCA  
14 protein assay kit (Pierce, Rockford, IL) according to the manufacturer's instruction  
15 (35), before reactions were quenched by the addition of DTT (33). The protein  
16 mixtures were diluted 8-fold in 50 mM Tris-HCl. Modified trypsin (Sigma, MO) was  
17 added to a final substrate-to enzyme ratio of 30:1 and the trypsin digests were  
18 incubated overnight at 37°C. The peptides from each digest solution were acidified to  
19 pH 3.0 with formic acid (FA) and loaded onto a Discovery DSC-18 Cartridge (Sigma,  
20 MO). Then peptides were desalted (5 ml of 0.1% FA) and eluted with 5 ml of a  
21 solution composed of 50% ACN with 0.1% FA.  
22 Peptides derived from insoluble fractions were analyzed qualitatively using shotgun  
23 peptide sequencing as previously described (36). For peptides derived from soluble  
24 fractions, equal amounts (100 µg) of sample were labelled with two iTRAQ reagents  
25 (Applied Biosystems, CA) following the manufacture's instruction; TRAQ-114 (non-

1 excysted) and iTRAQ-115 (excysted). Briefly, after desalting on a C18 cartridge the  
2 peptide mixture was lyophilized and re-suspended in 30  $\mu$ l of 0.5 M  
3 triethylammonium bicarbonate (N(Et)<sub>3</sub>HCO<sub>3</sub>), pH 8.5. The appropriate iTRAQ  
4 reagent (dissolved in 70  $\mu$ l ethanol) was added, allowed to react for 1 h at room  
5 temperature, and then quenched with 300  $\mu$ l of ddH<sub>2</sub>O.

6  
7 **Off-line strong cation exchange chromatography.** iTRAQ labelled peptides were  
8 then concentrated, mixed, and acidified to a total volume of 2.0 ml. They were then  
9 injected into an Agilent 1100 HPLC system with a Zorbax 300-SCX column (4.6 ID  
10  $\times$ 250 mm) (Agilent, Waldbronn, Germany). Solvent A was 5 mM KHPO<sub>4</sub> and 25%  
11 ACN (pH 3.0) and solvent B was 350 mM KCL in solvent A. Peptides were eluted  
12 from the column with a 40 min mobile phase gradient B of solvent B. A total of 30  
13 fractions were collected and samples were dried by a speed-vac prior to LC-MS/MS  
14 analysis.

15  
16 **On-line nano-LC ESI QqTOF MS analysis.** A nanobore LC system (Dionex,  
17 Sunnyvale, CA) which was interfaced to a QSTAR XL QqTOF mass spectrometer  
18 with a NanoSpray ion source (Applied Biosystems, Foster City, CA) was used for  
19 mass spectrometry. The Magic C18 100 A pore 75  $\mu$ m ID  $\times$ 150 mm (Picofrit  
20 Woburn, MA) was packed in-house. Solvent A was 3% ACN, 0.1% FA and 0.01%  
21 TFA and solvent B was 98% ACN, 0.1% FA and 0.01% TFA. Peptide mixtures  
22 (reconstituted in 200  $\mu$ l of 5% FA) were injected and eluted from the column with a  
23 110 min mobile phase solvent B gradient (5-5 % B in 5 min, 5-18% B in 10 min, 18-  
24 30% B in 65 min, 30 –60% B in 10 min, 60-90 % B in 10 min, and 90-90% in 5 min)  
25 at a flow rate of 250 nl/min. The mass spectrometer was operated in an information

1 dependent acquisition mode whereby following the interrogation of MS data ( $m/z$   
2 350-1500) using a 1 s survey scan, ions were selected for MS/MS analysis based on  
3 their intensity ( $>15$  cpm) and charge state (+2, +3, and +4). A total of 3 product ion  
4 scans (2,3,3 s each) were set from each survey scan. Rolling collision energies were  
5 chosen automatically based on the  $m/z$  and charge-state of the selected precursor ions.  
6 The integrated data appliance (IDA) Extensions II script was set to one repetition  
7 before dynamic exclusion.

8  
9 **Protein identification and quantification.** Identification and quantitation was  
10 performed using Pro ID (37) and ProQUANT software 1.1 (38) (Applied Biosystems)  
11 using the non-redundant database (NRDB) *C. parvum* sub-database (9811 entries)  
12 with an MS and MS/MS mass tolerance of 0.15 Da (39). Variable modification on  
13 methionine (oxidation, +16 Da) and fixed modification on cysteine  
14 (carbamidomethylation, +57 Da) residues were considered during the searching (39).  
15 Protein identification with confidence scores of  $>95\%$  were considered significant and  
16 the false positive rate was determined from decoy database (39) searching (data not  
17 shown). The identifications of all detected *C. parvum* proteins were then verified  
18 using BlastP at <http://www.ncbi.nlm.nih.gov/BLAST/>, or where appropriate at  
19 CryptoDB 3.3 (<http://cryptodb.org/cryptodb/>).

20  
21 Using ProQUANT software, quantification was based upon the signature peak areas  
22 ( $m/z$ : 114, 115) and corrected according to the manufacturer's instructions to account  
23 for isotopic overlap. Briefly, non-excysted oocysts (control) were labelled with  
24 isobaric tag 114 and relative quantification ratios of the identified proteins were  
25 calculated, averaged, and corrected for systematic error in labelling from the iTRAQ

1 peptides. For proteins in which every peptide's (labelled with tag 115) iTRAQ ratio  
 2 was 0, the average iTRAQ ratio was set to 0; an indication a protein which may be  
 3 highly down-regulated relative to the control. Similarly for those proteins where  
 4 every (tag 115) ratio was 9999, the average was set to 9999 (indicating a protein  
 5 which may be highly up-regulated). Statistically significant changes were weighted  
 6 by the error factor (a measure of the variation between the different iTRAQ ratios for  
 7 the reagent pair), and *p* value (95% confidence interval, which defined a range in  
 8 which the true average iTRAQ ratio was 95% likely to fall into). For instance, for a  
 9 ratio of 1.0 (indicating no change in expression levels), with an error factor of 2 (and  
 10 the corresponding 95% confidence interval of 0.5-2.0), the protein expression ratio  
 11 and error were reported as 1.0 (*p*<0.05 with an error factor of 2). Ratios in which the  
 12 total peak area was <40 counts were omitted. If there were fewer than 2 peptides  
 13 contributing towards an iTRAQ ratio average, the error factor and *p* values were not  
 14 valid, and were not calculated. Proteins which augmented significantly during  
 15 excystation had a *p*<0.05 and an error factor < 2.

16  
 17 **Bioinformatic analysis of 26 proteins which significantly augmented during**  
 18 **excystation.** Significantly over-expressed proteins were examined using BLASTP  
 19 both on the NCBI database and on ApiDB (<http://www.apidb.org/blast/>) to find  
 20 similarity with other Apicomplexan proteins or with proteins from unrelated species.  
 21 Only proteins identified by the BLASTP search with an expected value lower than  $10^{-10}$   
 22 were considered homologs. Searches were also performed for molecular traits and  
 23 domains of the putative proteins using SMART (<http://smart.embl-heidelberg.de/>).  
 24 The predicted coding sequence for the hypothetical protein cgd6\_4460 (N46) was  
 25 extended (results are currently unfinished in CryptoDB), by downloading a larger

- 1 portion of the AAEE0100002 contig. Gene sequences were predicted using Genscan
- 2 (<http://genes.mit.edu/GENSCAN.html>).

## 1 **Results**

### 2 **Protein expression in the soluble fractions of excysted and non-excysted oocysts.**

3 Using LC/MS with iCAT, 142 proteins were detected in both soluble fractions of  
4 excysted and non-excysted oocysts (supplemental table 1). Ribosomal proteins  
5 constituted a significant proportion (35: 24.7%) of proteins which were detected in  
6 both of the soluble fractions. Twenty-five proteins (17.6%) were detected which had  
7 hitherto been described as being only hypothetical proteins, e.g. N77, (Fig 3; Table 1).  
8 Six heat shock proteins and 17 secreted proteins were also expressed in both excysted  
9 and non-excysted oocysts. Many of the detected proteins are involved in  
10 infection/pathogenesis, energy pathways, e.g. glycolysis, cellular division and  
11 replication and DNA modification. The protein expression of 26 proteins was  
12 significantly greater ( $p < 0.05$  and error factor  $< 2$ ) in excysted oocysts (Table 1).

13

### 14 **Bioinformatics analysis of the 26 proteins which augmented during excystation.**

15 There were 18 ubiquitous proteins, which are highly conserved in many species from  
16 different phyla. Seven proteins which had hitherto been described as only being  
17 hypothetical proteins augmented significantly during excystation. Four are associated  
18 with ribosomes and four are heat shock proteins. A number of house keeping, e.g.  
19 lactate dehydrogenase (N102), or structural genes, e.g. histone H4 (N118), showed  
20 significant increases of expression. The protein Chro.50226 (N35) was a ubiquitous  
21 ribosomal protein L3. Eight proteins are restricted to the *Cryptosporidium* genus or to  
22 Apicomplexa, and consequently could play a specific role in the invasion process  
23 (Table 1). Five of these proteins appear to be restricted to the *Cryptosporidium* genus  
24 (Table 1). The hypothetical protein with signal peptide EAK88888 (N77) is highly  
25 conserved both in *C. parvum* and *C. hominis* (Table 1). EAK88888 demonstrates a

1 low similarity with proteins of the genus *Plasmodium*, however, the E value ( $1 \times 10^{-8}$ )  
2 is higher than the fixed cut off point. Therefore, EAK88888 is probably more closely  
3 related to similar proteins present in the genus *Plasmodium* than it appears from *C.*  
4 *parvum* and *C. hominis*. However, these proteins contain repetitive motifs that make  
5 the identification of a consensus sequence difficult. Three proteins [hypothetical  
6 protein cgd6\_4460 (N46), hypothetical protein cgd7\_4280 (N51), and Cpa135 protein  
7 (a135; N64)] demonstrate similarity with proteins from other Apicomplexa genera  
8 (*Plasmodium* and/or *Toxoplasma*), but not with proteins from other phyla (Table 1).

9

10 **Identification of proteins from the insoluble fractions of oocysts.** Using shotgun  
11 sequencing 122 proteins were detected from the non-excysted insoluble oocyst  
12 fraction (supplemental table 2). Thirty-four (27.9%) of these detected proteins were  
13 ribosomal and 26 of the proteins (21.3%) had hitherto been described as being only  
14 hypothetical proteins. Five heat shock proteins were also detected in non-excysted  
15 oocysts. As expected a number of surface antigens and oocyst wall associated  
16 proteins were also detected in this fraction. As per the soluble oocyst fractions, many  
17 of the detected proteins in the insoluble non-excysted oocyst fraction are involved in  
18 glycolysis, cellular division and replication and DNA modification. Also, 14 proteins  
19 (with unique accession numbers) were only detected from the excysted insoluble  
20 oocyst fractions (supplemental table 3).

21

22 **Surface, cytoskeletal and extra-cellular proteins.** During our investigation, in both  
23 soluble and insoluble fractions, we detected a number of *C. parvum* cytoskeletal and  
24 surface proteins. Detected cytoskeletal proteins included actin (N36) and alpha-  
25 tubulin (N277; Table 2). A number of proteins which are associated with extra-

1 cellular protein secretion were detected in both soluble and insoluble fractions. These  
2 proteins included a predicted secreted protein signal peptide (N65), aminopeptidase N  
3 (N109), and the secreted GP900 (N88; Table 2) (40). Moreover, among the  
4 sporozoite secreted proteins which were identified, all the *C. parvum* predicted LCCL  
5 containing proteins namely CCp2 (N69) and CCp3 (N70; Table 2), as well as the  
6 LCCL containing protein Cpa135 (N64; Table 1), were detected. Several oocyst wall  
7 and surface proteins were also detected, including glycoprotein Cp17 (N223), an  
8 oocyst wall protein precursor (N224), COWP1 (N225), and 15 kDa glycoprotein  
9 (N286; Table 2).

10

11 **Metabolic enzymes.** A number of proteins involved in metabolic reactions were  
12 detected in both soluble and insoluble fractions. These enzymes included enolase (2-  
13 phosphoglycerate dehydratase) (N98), glycerol-3-phosphate dehydrogenase (N106),  
14 and fructose-1,6-bisphosphate aldolase (N236; Table 2). A number of adenosine  
15 triphosphate (ATP) related enzymes were also detected, including secreted  
16 nucleoside-diphosphate kinase (N73; Table 2). A Pdr17p-like protein (N110), which  
17 may regulate lipid synthesis, and a pleckstrin homology (PH domain) containing  
18 protein (N124) were also detected (Table 2).

19

20 **Nucleic acids and protein synthesis and modification and replication.** In both  
21 soluble and insoluble oocyst fractions a number of enzymes which are involved in  
22 nucleic acid synthesis, repair and modification were detected. Examples of these  
23 included a small GTP binding protein rab1a (N91) and guanine nucleotide-binding  
24 protein (N115; Table 2). A number of enzymes were detected that would have key  
25 functions during the *Cryptosporidium* sp. replication, protein synthesis and

1 modification. Detected proteins with functions during replication included a GTP-  
2 binding nuclear protein ran/tc4 (N136), ribonucleotide reductase (N131), transcription  
3 regulator (N133), and a SEC14 domain containing protein (N264; Table 2). As well  
4 as, a number of ribosomal proteins, translation elongation factor 2 (EF-2; N137), and  
5 ubiquitin-activating enzyme E1 (N123) were detected, which have key roles during  
6 protein synthesis and in proteasome/ubiquitin systems, respectively (41) (Table 2). A  
7 number of enzymes associated with the protein structural modification were also  
8 detected, e.g. protein disulfide isomerase (N121), and Pre3p/proteasome regulatory  
9 subunit beta type 6, NTN hydrolase fold (N122; Table 2).

## 1 DISCUSSION

2 The first and most extensive proteome maps for all the life cycle stages of an  
3 Apicomplexan parasite were published in 2002 for *Plasmodium falciparum* (42).  
4 Proteome maps are available for the invasive stages of development of the other  
5 Apicomplexan parasites including the sporozoite of *Eimeria tenella*, as well as the  
6 tachyzoite of *T. gondii*, and *Neospora caninum* (42). Our study is the first major  
7 proteomic investigation of any *Cryptosporidium* species, and in particular of *C.*  
8 *parvum*, a major global human and animal pathogen. We examined the proteome of  
9 *C. parvum* oocysts at two important stages of its life cycle; the transmissive non-  
10 excysted oocyst and infective sporozoite stages. The identified proteins represent  
11 roughly 8% of the predicted proteome (19,20). Together with the sequencing of the  
12 *C. parvum* (20) and *C. hominis* (19) genomes, our study identified several potential  
13 targets both for immunotherapy and chemotherapy. Because of the high sequence  
14 similarity between the *C. hominis* and *C. parvum* genomes (19), the major pathogenic  
15 *Cryptosporidium* species for humans (10,11), it is conceivable that the development of  
16 an effective vaccine or a drug for one of these species would work on both of them.  
17 In the *C. parvum* life cycle, there are two motile stages, the sporozoite and the  
18 merozoite, which invade the host-cell membrane (Fig. 1). Sporozoites initiate the  
19 infection process, slipping out of the oocyst and invading the epithelial cells of the  
20 small intestine (2). It is conceivable that sporozoites as well as merozoites are more  
21 susceptible to drugs and the host immune system because they are exposed in the  
22 intestinal lumen, whereas the other parasite stages are intracellular.

23

24 One approach to the development of anticryptosporidial agents, has been to identify  
25 sporozoite and merozoite surface antigens involved in recognition, attachment, and

1 invasion of the host epithelial cells in order to block these interactions (423). We  
2 detected a number of surface and extra-cellular proteins. Glycosylinositol  
3 phospholipids (GIPLs) and glycosylphosphatidylinositol (GPI) protein anchors are  
4 abundant in the surface membranes of a wide variety of parasitic protozoa and are  
5 increasingly recognized as important modulators of the immune function during  
6 infection (12). The immunodominant *C. parvum* 17-kDa surface antigen (N223;  
7 Table 2) is GPI-anchored and parasite surface GIPLs are recognized by serum  
8 antibodies from infected patients (12). Furthermore, this work also confirms the  
9 expression of antigenic proteins, namely Cpa135 (N64) and GP900 (N88) (Tables 1  
10 and 2, respectively), which other than induce specific antibodies (40,44) can also elicit  
11 a cellular Th1 response (45).

12  
13 Importantly, during oocyst excystation, we identified 26 proteins which  
14 demonstrated significant expression increases. Thus, future vaccine development  
15 strategies could potentially select for antigens blocking the recognition and the  
16 attachment to host cells. Increased ribosomal protein expression may be due to the  
17 requirement of a rapid activation protein synthesis after a variable period of  
18 quiescence at the oocyst stage. The regulation of the ribosome and of the associated  
19 proteins has been observed in other species of the phylum Apicomplexa, e.g. *E.*  
20 *tenella* (46-48). Heat shock proteins (HSPs) are probably important for stress  
21 tolerance in the host environment and for the folding of newly synthesised proteins.  
22 Previous studies have found that the expression of HSPs occurred during the  
23 development of Apicomplexan parasites, and that HSPs are interesting targets for the  
24 host immune system (49). The level of HSP70 expression in *T. gondii* has been found  
25 to be higher in mouse-virulent than in mouse-avirulent strains (50). Recently, it has

1 been reported that *E. tenella* HSP90 is essential for the invasion of the host cell and  
2 that its expression increases in sporozoites which secrete this protein (51).  
3 Interestingly, we identified seven proteins which are unique for the genus  
4 *Cryptosporidium* and/or the phylum Apicomplexa (Table 1). Five of these proteins  
5 have a signal peptide at their N-terminus indicating that are secreted proteins. These  
6 proteins probably play a specialized role in the invasion machinery of the parasite.  
7 Apart from its signal peptide, the *cgd7\_4280* protein (N51; Table 1) is an  
8 Apicomplexan protein which does not demonstrate identifiable traits. There are  
9 paralogs of this gene both in *C. parvum* and in *C. hominis* [hypothetical protein  
10 *cgd7\_1270* (N49; table 2) and hypothetical protein Chro.70152], suggesting that these  
11 proteins belong to a more extensive protein family. The *cgd6\_4460* (N46) protein  
12 belongs to an Apicomplexan family sharing a peculiar architecture, because they  
13 contain both a histone deacetylase (HDAC) interacting domain and an armadillo  
14 repeat (ARM) domain. Histone deacetylases are involved in higher order chromatin  
15 assembly (52) and ARM repeat proteins are involved in various processes, including  
16 intracellular signalling and cytoskeletal regulation (53).

17  
18 Cpa135 has been already characterised, it is secreted by the apical complex  
19 prior to host cell invasion and Cpa135-related proteins are a distinct family among the  
20 apicomplexan (LCCL) proteins (52). Accordingly with the present data, the  
21 expression of Cpa135 increases four-fold within 30 min after excystation (52). On the  
22 whole, three proteins containing LCCL domains (including Cpa135), with peculiar  
23 domain architecture, e.g. CpCC2 (N69) and CpCC3 (N70) were detected. These  
24 proteins are composed of various adhesive motifs (ricin B, LCCL and discoidin),  
25 suggesting these proteins are involved in some adhesion process. They also have

1 closely related homologs in *P. falciparum*, namely PfCCp1, PfCCp2 and PfCCp3 that  
2 are orthologs to Cpa135 (also named CpCCp1), CpCCp2 and CpCC3 respectively  
3 (52,54). Interestingly, our results demonstrated that these proteins are expressed  
4 simultaneously in both oocysts and free sporozoites, whereas all the *P. falciparum*  
5 orthologs have gametocyte stage specific expression of these genes (54). This fact  
6 suggests that these proteins require a coordinate expression to exert their role.

7  
8 This study is the first major proteomic investigation of its kind on any  
9 *Cryptosporidium* species. We ascertained the expression of many formerly putative  
10 proteins and the presence of several secreted or surface proteins in sporozoites which  
11 are restricted to the Apicomplexa or to *Cryptosporidium* genus. These findings could  
12 favor further studies for the identification and role of specific molecules involved in  
13 the motility, host recognition and invasion. Interestingly, three Apicomplexa-specific  
14 proteins and five *Cryptosporidium* sp.-specific proteins augment in excysted invasive  
15 sporozoites. These eight proteins represent promising targets for developing vaccines  
16 or chemotherapies that could block parasite entry into host cells. Therefore our study  
17 represents a substantial step forward towards increasing our understanding of  
18 *Cryptosporidium* sp. biology, the molecular mechanisms of parasite entry, as well as  
19 the development of therapy to combat cryptosporidiosis.

1 **ACKNOWLEDGMENTS**

2 W.J.S. was supported by The Northern Ireland Centre of Excellence in Functional  
3 Genomics, with funding from the European Union (EU) Program for Peace and  
4 Reconciliation, under the Technology Support for the Knowledge-Based Economy.

5 E.P. and F.T. were partially supported by the grant of the Istituto Superiore di Sanità,  
6 5th National AIDS Project, contract 50F/H. We are grateful to Daniele Tonanzi for  
7 their excellent oocyst purification technical support. We thank Lorenza Putignani for  
8 generating transmission electron microscopy images.

## 1 REFERENCES

- 2 1. Doganci T, Araz E, Ensari A, Tanyuksel M, Doganci L (2002) Detection of  
3 *Cryptosporidium parvum* infection in childhood using various techniques. *Med Sci*  
4 *Monit*, **8**, 223-226.
- 5 2. Fayer R, Speer CA, Dubey JP. General biology of *Cryptosporidium*: In: R. Fayer  
6 (ed.), *Cryptosporidium* and cryptosporidiosis. Boca Raton: CRC Press; 1997. p. 1-42.
- 7 3. Xiao L, Fayer R, Ryan U, Upton SJ (2004) *Cryptosporidium* taxonomy: Recent  
8 advances and implications for public health. *Clin Microbiol Rev*, **17**, 72-97.
- 9 4. Blackman MJ, Bannister LH (2001) Apical organelles of Apicomplexa: biology  
10 and isolation by subcellular fractionation. *Mol Biochem Parasitol*, **117**, 11-25.
- 11 5. Smith HV, Nichols RAB, Grimason AM (2005) *Cryptosporidium* excystation and  
12 invasion: getting to the guts of the matter. *Trends Parasitol*, **21**, 133-142.
- 13 6. Sunnotel O, Lowery CJ, Moore JE, Dooley JS, Xiao L, Millar BC, Rooney PJ,  
14 Snelling WJ (2006) Under the microscope: *Cryptosporidium*. *Lett Appl Microbiol*, **42**,  
15 7-14.
- 16 7. McCole DF, Eckmann L, Laurent F, Kagnoff MF (2000) Intestinal epithelial cell  
17 apoptosis following *Cryptosporidium parvum* infection. *Infect Immun*, **68**, 1710–  
18 1713.
- 19 8. Fayer R, Morgan U, Upton SJ (2000) Epidemiology of *Cryptosporidium*:  
20 transmission, detection, and identification. *Int J Parasitol*, **30**, 1305–1322.
- 21 9. Caccio SM (2005) Molecular epidemiology of human cryptosporidiosis.  
22 *Parassitologia*, **47**, 185-192.
- 23 10. Chen XM, O'Hara SP, Huang BQ, Splinter PL, Nelson JB, LaRusso NF (2005)  
24 Localized glucose and water influx facilitates *Cryptosporidium parvum* cellular

- 1 invasion by means of modulation of host-cell membrane protrusion. *Proc Natl Acad*  
2 *Sci USA*, **102**, 6338-6343.
- 3 11. McDonald V (2000) Host cell-mediated responses to infection with  
4 *Cryptosporidium*. *Parasite Immunol*, **22**, 597-604.
- 5 12. Priest JW, Mehlert A, Moss DM, Arrowood MJ, Ferguson MA (2006)  
6 Characterization of the glycosylphosphatidylinositol anchor of the immunodominant  
7 *Cryptosporidium parvum* 17-kDa antigen. *Mol Biochem Parasitol*, **149**, 108-112.
- 8 13. MacKenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE,  
9 Kazmierczak JJ, Addiss DG, Fox KR, Rose JB (1994) A massive outbreak in  
10 Milwaukee of cryptosporidium infection transmitted through the public water supply.  
11 *N Engl J Med*, **331**, 161-167.
- 12 14. Corso PS, Kramer MH, Blair KA, Addiss DG, Davis JP, Haddix AC (2003) Cost  
13 of illness in the 1993 waterborne *Cryptosporidium* outbreak, Milwaukee, Wisconsin.  
14 *Emerg Infect Dis*, **9**, 426-431.
- 15 15. Zhu G, LaGier MJ, Hirose S, Keithly JS (2000) *Cryptosporidium parvum*:  
16 functional complementation of a parasite transcriptional coactivator CpMBF1 in  
17 yeast. *Exp Parasitol*, **96**, 195-201.
- 18 16. Craun GF, Calderon RL, Craun MF (2005) Outbreaks associated with recreational  
19 water in the United States. *Int J Environ Health Res*, **15**, 243-262.
- 20 17. Putignani L (2005) The unusual architecture and predicted function of the  
21 mitochondrion organelle in *Cryptosporidium parvum* and *hominis* species: the strong  
22 paradigm of the structure-function relationship. *Parassitologia*, **47**, 217-225.
- 23 18. Adkins JN, Mottaz HM, Norbeck AD, Gustin JK, Rue J, Clauss TR, Purvine SO,  
24 Rodland K, Heffron F, Smith RD (2006) Analysis of the *Salmonella typhimurium*

- 1 proteome through environmental response towards infectious conditions. *Mol Cell*  
2 *Proteomics*, **5**, 1450-1461.
- 3 19. Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, Puiu D, Manque P,  
4 Akiyoshi D, Mackey AJ, Pearson WR, Dear PH, Bankier AT, Peterson DL,  
5 Abrahamsen MS, Kapur V, Tzipori S, Buck GA (2004) The genome of  
6 *Cryptosporidium hominis*. *Nature*, **431**, 1107-1112.
- 7 20. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA,  
8 Deng M, Liu C, Widmer G, Tzipori S, Buck GA, Xu P, Bankier AT, Dear PH,  
9 Konfortov BA, Spriggs HF, Iyer L, Anantharaman V, Aravind L, Kapur V (2004)  
10 Complete genome sequence of the apicomplexan, *Cryptosporidium parvum*. *Science*,  
11 **304**, 441-445.
- 12 21. Templeton TJ, Iyer LM, Anantharaman V, Enomoto S, Abrahante JE,  
13 Subramanian GM, Hoffman SL, Abrahamsen MS, Aravind L (2004) Comparative  
14 analysis of apicomplexa and genomic diversity in eukaryotes. *Genome Res*, **14**, 1686-  
15 1695.
- 16 22. Gut J, Nelson RG (1999) *Cryptosporidium parvum*: synchronized excystation in  
17 vitro and evaluation of sporozoite infectivity with a new lectin-based assay. *J*  
18 *Eukaryot Microbiol*, **46**, 56S-57S.
- 19 23. Wu XD, Kircher RA, McVerry PH, Malinzak DA (2000) Characterization of post-  
20 translationally modified recombinant protein using liquid chromatography/mass  
21 spectrometry. *Dev Biol (Basel)*, **103**, 61-67.
- 22 24. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S,  
23 Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlett-  
24 Jones M, He F, Jacobson A, Pappin DJ (2004) Multiplexed protein quantitation in

- 1 *Saccharomyces cerevisiae* using amine-reactive isobaric tagging reagents. *Mol Cell*  
2 *Proteomics*, **3**, 1154-1169.
- 3 25. Kislinger T, Gramolini AO, Pan Y, Rahman K, MacLennan DH, Emili A (2005)  
4 Proteome dynamics during C2C12 myoblast differentiation. *Mol Cell Proteomics*, **4**,  
5 887-901.
- 6 26. Truong Q, Ferrari BC (2006) Quantitative and qualitative comparisons of  
7 *Cryptosporidium* faecal purification procedures for the isolation of oocysts suitable  
8 for proteomic analysis. *Int J Parasitol*, **36**, 811-819.
- 9 27. Arrowood JM, Sterling CR (1987) Isolation of *Cryptosporidium* oocysts and  
10 sporozoites using discontinuous sucrose and isopycnic Percoll gradients. *J Parasitol*,  
11 **73**, 314-319.
- 12 28. Bukhari Z, Marshall MM, Korich DG, Fricker CR, Smith HV, Rosen J, Clancy JL  
13 (2000) Comparison of *Cryptosporidium parvum* viability and infectivity assays  
14 following ozone treatment of oocysts. *Appl Environ Microbiol*, **66**, 2972-2980.
- 15 29. Mele R, Gomez Morales MA, Tosini F, Pozio E (2004) *Cryptosporidium parvum*  
16 at different developmental stages modulates host cell apoptosis in vitro. *Infect Immun*,  
17 **72**, 6061-6067.
- 18 30. Riggs MW, Cama VA, Leary HL Jr, Sterling CR (1994) Bovine antibody against  
19 *Cryptosporidium parvum* elicits a circumsporozoite precipitate-like reaction and has  
20 immunotherapeutic effect against persistent cryptosporidiosis in SCID mice. *Infect*  
21 *Immun*, **62**, 1927-1939.
- 22 31. Mandal P, Chakraborty P, Sau S, Mandal NC (2006) Purification and  
23 characterization of a deoxyriboendonuclease from *Mycobacterium smegmatis*. *J*  
24 *Biochem Mol Biol*, **39**, 140-144.

- 1 32. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST (2005)  
2 Different techniques for urinary protein analysis of normal and lung cancer patients.  
3 *Proteomics*, **5**, 1140-1149.
- 4 33. Ranish JA, Yi EC, Leslie DM, Purvine SO, Goodlett DR, Eng J, Aebersold R  
5 (2003) The study of macromolecular complexes by quantitative proteomics. *Nat*  
6 *Genet*, **33**, 349-355.
- 7 34. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC,  
8 Lipton SA (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to  
9 neuronal cell death. *Science*, **297**, 1186-1190.
- 10 35. Prozialeck WC, Fay MJ, Lamar PC, Pearson CA, Sigar I, Ramsey KH (2002)  
11 *Chlamydia trachomatis* disrupts N-cadherin-dependent cell-cell junctions and  
12 sequester  $\beta$ -catenin in human cervical epithelial cells. *Infect Immun*, **70**, 2605-2613.
- 13 36. Wolters DA, Washburn MP, Yates Jr 3<sup>rd</sup> (2001) An automated multidimensional  
14 protein identification technology for shotgun proteomics. *Anal Chem*, **73**, 5683-5690.
- 15 37. Smith JA, Blanchette RA, Burnes TA, Jacobs JJ, Higgins L, Witthuhn BA, David  
16 AJ, Gillman JH. (2006) Proteomic comparison of needles from blister rust-resistant  
17 and susceptible *Pinus strobus* seedlings reveals upregulation of putative disease  
18 resistance proteins. *Mol Plant Microbe Interact*, **19**, 150-160.
- 19 38. Shadforth IP, Dunkley TPJ, Lilley KS and Bessant C (2005) i-Tracker: For  
20 quantitative proteomics using iTRAQ™. *BMC Genomics*, **6**, 145.
- 21 39. Tang WH, Halpern BR, Shilov IV, Seymour SL, Keating SP, Loboda A, Patel  
22 AA, Schaeffer DA, Nuwaysir LM (2005) Discovering known and unanticipated  
23 protein modifications using MS/MS database searching. *Anal Chem*, **77**, 3931-3946.

- 1 40. Barnes DA, Bonnin A, Huang JX, Gousset L, Wu J, Gut J, Doyle P, Dubremetz  
2 JF, Ward H, Petersen C (1998) A novel multi-domain mucin-like glycoprotein of  
3 *Cryptosporidium parvum* mediates invasion. *Mol Biochem Parasitol*, **96**, 93-110.
- 4 41. Gonzalez J, Bai G, Frevert U, Corey EJ, Eichinger D (1999) Proteasome-  
5 dependent cyst formation and stage-specific ubiquitin mRNA accumulation in  
6 *Entamoeba invadens*. *Eur J Biochem*, **264**, 897-904.
- 7 42. Belli SI, Walker RA, Flowers SA (2005) Global protein expression analysis in  
8 apicomplexan parasites: current status. *Proteomics*, **5**, 918-924.
- 9 43. O'Connor RM, Kim K, Khan F, Ward HD (2003) Expression of *Cpgp40/15* in  
10 *Toxoplasma gondii*: a surrogate system for the study of *Cryptosporidium* glycoprotein  
11 antigens. *Infect Immun*, **71**, 6027-6034.
- 12 44. Tosini F, Caccio S, Tamburrini A, La Rosa G, Pozio E (1999) Identification and  
13 characterisation of three antigenic proteins from *Cryptosporidium parvum* sporozoites  
14 using a DNA library expressing poly-histidine tagged peptides. *Int J Parasitol*, **29**,  
15 1925-1933.
- 16 45. Gomez Morales MA, Mele R, Ludovisi A, Bruschi F, Tosini F, Rigano R, Pozio E  
17 (2004) *Cryptosporidium parvum*-specific CD4 Th1 cells from sensitized donors  
18 responding to both fractionated and recombinant antigenic proteins. *Infect Immun*, **72**,  
19 1306-1310.
- 20 46. Waters AP, Syin C, McCutchan TF (1989) Developmental regulation of stage-  
21 specific ribosome populations in *Plasmodium*. *Nature*, **342**, 438-440.
- 22 47. Li J, McConkey GA, Rogers MJ, Waters AP, McCutchan TR (1994) *Plasmodium*:  
23 the developmentally regulated ribosome. *Exp Parasitol*, **78**, 437-441.

- 1 48. Schaap D, Arts G, van Poppel NF, Vermeulen AN (2005) De novo ribosome  
2 biosynthesis is transcriptionally regulated in *Eimeria tenella*, dependent on its life  
3 cycle stage. *Mol Biochem Parasitol*, **139**, 239-248.
- 4 49. Sharma YD (1992) Structure and possible function of heat-shock proteins in  
5 *Falciparum* malaria. *Comp Biochem Physiol B*, **102**, 437-444.
- 6 50. Lyons RE, Johnson AM (1995) Heat shock proteins of *Toxoplasma gondii*.  
7 *Parasite Immunol*, **17**, 353-359.
- 8 51. Peroval M, Pery P, Labbe M (2006) The heat shock protein 90 of *Eimeria tenella*  
9 is essential for invasion of host cell and schizont growth. *Int J Parasitol*, **36**, 1205-  
10 1215.
- 11 52. Tosini F, Agnoli A, Mele R, Gomez Morales MA, Pozio E. (2004) A new  
12 modular protein of *Cryptosporidium parvum*, with ricin B and LCCL domains,  
13 expressed in the sporozoite invasive stage. *Mol Biochem Parasitol*, **134**, 137-147.
- 14 53. Nakayama J, Xiao G, Noma K, Malikzay A, Bjerling P, Ekwall K, Kobayashi R,  
15 Grewal SI (2003) Alp13, an MRG family protein, is a component of fission yeast Clr6  
16 histone deacetylase required for genomic integrity. *EMBO J*, **22**, 2776-2787.
- 17 54. Pradel G, Wagner C, Mejia C, Templeton TJ (2006) *Plasmodium falciparum*: Co-  
18 dependent expression and co-localization of the PfCCp multi-adhesion domain  
19 proteins. *Exp Parasitol*, **112**, 263-268.

1 **Table 1:** Summary of the bioinformatic analysis of the 26 proteins which showed significant expression increases during excystation.

<b>Ribosomal</b>				
<b>N</b>	<b>Accession number</b>	<b>Protein name</b>	<b>Homologs</b>	<b>Domains</b>
5	gi 66358116	40S ribosomal protein S7	LC R	none detected
17	gi 32398896	60S ribosomal protein-like, probable	LC R	none detected
31	gi 46229456	60S ribosomal protein L35A, transcript identified by EST	LC R	none detected
35	gi 67594773	hypothetical protein Chro.50226 (ribosomal protein L3), note: it is not present in the <i>C. parvum</i> annotated proteins	LC R	none detected
<b>Undetermined function</b>				
<b>N</b>	<b>Accession number</b>	<b>Protein name</b>	<b>Homologs</b>	<b>Domains</b>
44	gi 66357812	hypothetical protein cgd5_1370	<i>C. hominis</i>	not detected
46	gi 66475922	hypothetical protein cgd6_4460	Apicomplexa	HDAC interact domain and ARM domain
<b>Heat shock</b>				
<b>N</b>	<b>Accession number</b>	<b>Protein name</b>	<b>Homologs</b>	<b>Domains</b>
58	gi 46229711	HSP70, transcripts identified by EST	LC S	none detected
59	gi 8515208	HSP70	LC S	none detected
61	gi 3273568	HSP90	LC S	none detected
62	gi 66359492	HSP90	U S	none detected
<b>Secreted</b>				
<b>N</b>	<b>Accession number</b>	<b>Protein name</b>	<b>Homologs</b>	<b>Domains</b>
42	gi 66359420	hypothetical protein cgd3_3370	<i>C. hominis</i>	signal peptide
51	gi 66363232	hypothetical protein cgd7_4280	Apicomplexa	signal peptide

52	gi 32398968	hypothetical garp protein, possible	<i>C. hominis</i>	signal peptide
64	gi 20513131	Cpa135 protein	Apicomplexa	signal peptide, ricin B, and LCCL
68	gi 46229371	protein with signal peptide and 2 <i>Cryptosporidium</i> -specific paralogs, putative secreted protein EAK90189	<i>C. hominis</i>	signal peptide
77	gi 46227968	hypothetical protein with signal peptide EAK88888	<i>C. hominis</i>	signal peptide
<b>Metabolic enzymes</b>				
N	Accession number	Protein name	Homologs	Domains
102	gi 10444017	lactate dehydrogenase	LC H	none detected
105	gi 46229140	glyceraldehyde 3-phosphate dehydrogenase	LC H	none detected
107	gi 66359800	acetaldehyde reductase plus alcohol dehydrogenase (AdhE) of possible bacterial origin	LC H	none detected
108	gi 46229859	phosphoglycerate kinase 1	LC H	none detected
<b>Nucleic acids and protein synthesis and modification and replication</b>				
N	Accession number	Protein name	Homologs	Domains
84	gi 51951320	thioredoxin peroxidase-like protein	LC H	none detected
118	gi 46228775	histone H4	LC H	none detected
119	gi 32398654	protein disulphide isomerase, probable	LC H	none detected
120	gi 32398904	Mov34/MPN/PAD-1 family proteasome regulatory subunit, probable	LC H	none detected
127	gi 46229603	EF-1-gamma (glutathione S-transferase family)	LC R	none detected
135	gi 32398975	EF-1-alpha	LC R	none detected

1 LC: largely conserved among different phyla, R: proteins involved in protein synthesis and/or associated with ribosomes, H: house keeping  
2 genes or structural genes, S: heat shock proteins, LCCL *Limulus* factor C, Coch 5B2, LG11, HDAC: histone deacetylase, and ARM: armadillo  
3 repeat.

- 1 **Table 2:** Data from of a subset of 28 proteins, from the total 303 *Cryptosporidium parvum* proteins, which were identified during this
- 2 investigation. Two proteins (N115 and N136) were not present in the GenBank database, thus their accession numbers refer to *C. parvum*
- 3 predicted proteins (prefix cgd) in CryptoDB.

<b>Cytoskeletal</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession number</b>	<b>Protein name</b>
36	5.96	5.96	gi 20799249	actin
277	2	2.01	gi 2522417	alpha-tubulin
<b>Undetermined function</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession number</b>	<b>Protein name</b>
49	2.01	2.06	gi 66362692	hypothetical protein cgd7_1270
<b>Secreted</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession number</b>	<b>Protein name</b>
65	5.6	5.6	gi 46227507	predicted secreted protein, signal peptide
69	7.25	7.26	gi 46229704	CpCCp2; extracellular protein with a signal peptide, ricin, discoidin, NEC, LCCL, 2 levanase exan-specific cysteine-rich repeat (apicA repeat)
70	2.78	2.82	gi 46227948	CpCCp3, multidomain extracellular protein with a signal peptide, and the following architecture:LH2, LCCLCCL, pentraxin, and 2xLCCL
73	2	2.01	gi 46227296	signal peptide containing protein having a NDK (nucleoside-diphosphate kinase) domain, transcript identified by EST
88	10.16	10.17	gi 4063042	GP900; mucin-like glycoprotein
109	4.02	4.02	gi 46228639	zinc in/aminopeptidase N like metalloprotease

<b>Surface and oocyst wall</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession number</b>	<b>Protein name</b>
223	8.01	8.02	gi 30268708	Cp17 antigen precursor
224	2.48	2.49	gi 32398662	oocyst wall protein precursor, possible
225	6.19	6.98	gi 46229286	CpCOWP1, oocyst wall protein with type I and type II cysteine-rich repeats
286	6.12	6.12	gi 8671728	15 kDa glycoprotein gp15
<b>Metabolic enzymes</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession Number</b>	<b>Protein name</b>
98	6	6	gi 66357920	enolase (2-phosphoglycerate dehydratase)
106	2	2.01	gi 66356424	glycerol-3-phosphate dehydrogenase
110	2.01	2.02	gi 66475304	Pdr17p-like protein
124	24.2	24.2	gi 66360002	pleckstrin homology (PH domain) containing protein
236	11.7	11.7	gi 46227620	fructose-1,6-bisphosphate aldolase [EC:4.1.2.13] [ <i>Cryptosporidium parvum</i> ]
<b>Nucleic acids and protein synthesis and modification and replication</b>				
<b>N</b>	<b>Unused ProtScore</b>	<b>Total ProtScore</b>	<b>Accession Number</b>	<b>Protein name</b>
91	2	2.01	gi 32398899	small GTP binding protein Rab1a, probable
115	2	2	cgd2_1870	guanine nucleotide-binding protein, putative
121	2	2.02	gi 46229649	protein disulfide isomerase, signal peptide plus ER retention motif
122	2.01	2.01	gi 66358282	Pre3p/proteasome regulatory subunit beta type 6, NTN hydrolase fold
123	2.03	2.05	gi 46226970	ubiquitin-activating enzyme E1 (UBA)
131	1.52	1.53	gi 46228920	ribonucleotide reductase small subunit, duplicated adjacent gene

133	2.02	2.03	gi 66362450	transcription regulator
136	2	2	cgd7_220	GTP-binding nuclear protein ran/tc4
137	4.02	4.03	gi 46228834	Eft2p GTPase; translation elongation factor 2 (EF-2)
264	1.7	1.7	gi 46228972	SEC14 domain containing protein

1 **Figure legends.**

2 **Fig. 1 (A through C):** The structure of *Cryptosporidium parvum* and its life-cycle  
3 stages.

4  
5 (A) A transmission electron microscopy image of a non-excysted *C. parvum* oocyst,  
6 which contains 4 sporozoites. Three of the sporozoites (out of four) are visible, one in  
7 a longitudinal plane, and the other two in transverse planes; AP: anterior pole, OW:  
8 oocyst wall, N: nucleus, PP: posterior pole, S: scissure, and SPO: sporozoite.

9  
10 (B) Transverse section of a free excysted sporozoite showing the apical complex and  
11 the organelles; AC: apical complex, DG: dense granules, M: micronemes, MT:  
12 mitochondrion, N: nucleus, R: rhoptry, and RB: refractile body.

13  
14 (C) The stages of *Cryptosporidium* spp. life-cycle (5). During this investigation  
15 oocysts were analysed at both non-excysted (x) and (excysted) (y) stages of this cycle.  
16 Upon ingestion by the host, sporozoites are released and adhere directly to the  
17 intestinal epithelial cells of the host. Cell invasion by sporozoite is followed by  
18 intracellular development to trophozoite. Trophozoite undergo schizogony to form  
19 schizonts. Asexual replication occurs by re-infection of merozoites, released by type I  
20 schizont. Development of type II from type I schizont is the initial step of the asexual  
21 reproductive cycle. Type II merozoites are released and re-infect neighbouring cells  
22 where they develop into microgametocytes (male) or macrogametocytes (female). The  
23 macrogametocyte is fertilised by released microgametes and matures into a zygote,  
24 which undergoes further development into an oocyst. Two types of oocysts are

1 released: (I) thick-walled oocysts, which are excreted in the faeces, or, (II) thin walled  
2 oocysts for endogenous re-infection (auto-infection).

3


4 **Fig. 2:** Scheme of the overall workflow used for the proteomic analysis of  
5 *Cryptosporidium parvum*.

6

7 **Fig. 3:** Example of MS/MS spectrum of peptide FPTLTGFNR (hypothetical protein  
8 with signal peptide EAK88888; N77) from a protein digestion mixture prepared by  
9 labelling two separate digests with tag 114 and 115, respectively and combining the  
10 reaction mixtures in a 1:1 ratio. (A) Isotopic distribution of a doubly charged  
11 precursor  $[M+2H]^{2+}$ ,  $m/z$  598.8164, (B) low mass region showing the signature ions  
12 used for quantification. The peptide was labelled by isobaric tags at the N-terminus.


1 **Figs. 1A and 1B:**

2



3


1 Fig. 1C:



2


1 **Fig. 2:**

2



1 Fig. 3:

2



3

4